Solid Biosciences Inc. (SLDB) Stock Price & Analysis
Solid Biosciences Inc. (SLDB) fell 1.88% to USD 7.83 as of July 25, 2026 at 06:50 UTC, according to Nexqual real-time market data.
SLDB last closed at USD 7.98; the session ranged USD 7.7–8.09 on volume of 1,076,074 shares. Market capitalization is $770.86M, with a 52-week range of USD 3.79–11.45 (NMS). Source: Nexqual, July 25, 2026 at 06:50 UTC.
Key Statistics (as of July 25, 2026 at 06:50 UTC)
| Price | USD 7.83 |
|---|---|
| Change | ▼ 1.88% (down) |
| Previous Close | USD 7.98 |
| Open | USD 8.07 |
| Day Range | USD 7.7 – 8.09 |
| 52-Week Range | USD 3.79 – 11.45 |
| Volume | 1,076,074 shares |
| Market Cap | $770.86M |
| Exchange | NMS |
Technical Analysis (SLDB)
Nexqual's technical model rates SLDB "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:50 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.74 (neutral) |
| vs SMA50 | Below (USD 8.17) |
| MACD | -0.1 (negative) |
Analyst Ratings (SLDB)
Wall Street analysts rate SLDB "Strong Buy" based on 12 analysts, with a mean price target of USD 17.5 (range USD 11–26), per Nexqual as of July 25, 2026 at 06:50 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 17.5 |
| High Target | USD 26 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 13 / 0 / 0 |
Earnings (SLDB)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.46 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.53 vs est -0.52 ▼ miss |
| 2025-09-30 | USD -0.48 vs est -0.44 ▼ miss |
| 2025-06-30 | USD -0.42 vs est -0.49 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:50 UTC.
Financials & Fundamentals (SLDB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -57.37% |
| Debt / Equity | 5.52 |
| Current Ratio | 13.1 |
| Total Cash | $380.68M |
| Total Debt | $20.67M |
| Free Cash Flow | $-110.97M |
Source: Nexqual, July 25, 2026 at 06:50 UTC.
Financial Health Score (SLDB)
Nexqual rates Solid Biosciences Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 06:50 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $381M cash vs $21M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$172M |
| Efficiency | Critical — ROE -57%, ROA -32.0% |
Ownership (SLDB)
| Insider Ownership | +0.74% |
|---|---|
| Institutional Ownership | +104.73% |
| Shares Outstanding | 98.45M |
| Float | 51.04M |
| Short % of Float | +20.65% |
Source: Nexqual, July 25, 2026 at 06:50 UTC.
Leadership (SLDB)
Solid Biosciences Inc. is led by Alexander G. Cumbo (age 54), President, CEO & Director, per Nexqual as of July 25, 2026 at 06:50 UTC.
| President, CEO & Director | Alexander G. Cumbo (age 54) |
|---|---|
| Co-founder, Strategic Advisor to the CEO & Director | Ilan Ganot (age 51) |
| COO & Secretary | David Tyronne Howton Jr. (age 53) |
| CFO & Treasurer | Kevin Tan C.F.A. (age 47) |
| Chief Technology Officer | Paul Herzich (age 47) |
Major Backers & Investors (SLDB)
Notable institutional backers of Solid Biosciences Inc. include Perceptive Advisors Llc, Bain Capital Life Sciences Investors, LLC, RA Capital Management, L.P., according to Nexqual as of July 25, 2026 at 06:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Perceptive Advisors Llc | 12.09% |
| Bain Capital Life Sciences Investors, LLC | 9.96% |
| RA Capital Management, L.P. | 9.49% |
| Siren, L.L.C. | 7.81% |
| Vestal Point Capital, LP | 5.08% |
| Janus Henderson Group PLC | 4.07% |
| Fidelity | 3.93% |
| FMR, LLC | 3.66% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.06% |
Source: Nexqual, July 25, 2026 at 06:50 UTC.
From Solid Biosciences Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
- The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.
- In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid.
- The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VYGR | Voyager Therapeutics, Inc. | USD 3.1 | ▲ 0% |
| RGNX | REGENXBIO Inc. | USD 9.73 | ▼ 4.61% |
| MGTX | MeiraGTx Holdings plc | USD 11.77 | ▼ 3.21% |
| WVE | Wave Life Sciences Ltd. | USD 5.81 | ▲ 1.22% |
| STOK | Stoke Therapeutics, Inc. | USD 29.3 | ▲ 1.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:50 UTC. This page is informational and not investment advice.